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Abstract
Rationale: Both atopy and smoking are known to be associated with increased bronchial responsiveness. Fraction of nitric
oxide (NO) in the exhaled air (FENO), a marker of airways inflammation, is decreased by smoking and increased by atopy. NO
has also a physiological bronchodilating and bronchoprotective role.
Objectives: To investigate how the relation between FENO and bronchial responsiveness is modulated by atopy and
smoking habits.
Methods: Exhaled NO measurements and methacholine challenge were performed in 468 subjects from the random sample
of three European Community Respiratory Health Survey II centers: Turin (Italy), Gothenburg and Uppsala (both Sweden).
Atopy status was defined by using specific IgE measurements while smoking status was questionnaire-assessed.
Main Results: Increased bronchial responsiveness was associated with increased FENO levels in non-smokers (p=0.02) and
decreased FENO levels in current smokers (p=0.03). The negative association between bronchial responsiveness and FENO
was seen only in the group smoking less ,10 cigarettes/day (p=0.008). Increased bronchial responsiveness was associated
with increased FENO in atopic subjects (p=0.04) while no significant association was found in non-atopic participants. The
reported interaction between FENO and smoking and atopy, respectively were maintained after adjusting for possible
confounders (p-values,0.05).
Conclusions: The present study highlights the interactions of the relationship between FENO and bronchial responsiveness
with smoking and atopy, suggesting different mechanisms behind atopy- and smoking-related increases of bronchial
responsiveness.
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Introduction
Bronchial hyperresponsiveness is one of the hallmarks of asthma
and measurement of bronchial responsiveness has been used
clinically for over 30 years for asthma diagnosis and monitoring
[1]. Exhaled nitric oxide has been introduced as a tool for asthma
diagnosis in subjects with symptoms of asthma [2] and for the
monitoring of asthma therapy [3]. Fraction of nitric oxide in the
exhaled air (FENO) is a non-invasive marker of steroid-sensitive
inflammation in the airways [4]. NO has also known bronchodi-
lating and bronchoprotective physiological roles [5]. Apart from
asthma, bronchial responsiveness and FENO are also associated
with other factors such as atopy and smoking. Atopy is related
both to increased bronchial responsiveness [6] and increased
FENO [7], while smoking is associated with increased bronchial
responsiveness [8] and decreased FENO [9].
A positive correlation between bronchial responsiveness and
FENO has been found among subjects with allergic asthma [10]
and in population-based studies of adults [11,12] and children
[13]. In these studies, after stratification for atopy, the association
between bronchial responsiveness and increased FENO was
statistically significant only among atopic individuals [11,13].
An interaction of bronchial responsiveness with smoking and
atopy has been previously suggested in a Spanish population-based
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bronchial responsiveness only in non-atopic subjects. On the other
hand, FENO is reduced to the same extent by current smoking in
non-atopics and atopics [15]. This suggests that the association
between FENO and bronchial responsiveness is affected both by
smoking and atopy. No previous studies have analyzed how
smoking and smoking amount influences the relationship between
bronchial responsiveness and FENO.
The aim of the present study was to investigate the association
between bronchial responsiveness and FENO, with special regard
to how this association is influenced by smoking, smoking amount
and atopy.
Methods
Ethics Statement
Written informed consent was obtained from each subject
before inclusion in the study. The protocol was approved by the
Uppsala Ethics Committee (decision 131/1999 for Swedish
multicentre application for Uppsala and Gothenburg) and Verona
Ethics Committee (decision 74/1998 for Italian multicentre
ECHRS II application including Turin).
Study participants
The European Community Respiratory Health Survey
(ECRHS) is an international multicenter study of asthma and
allergy. The first part, ECRHS I, was conducted in 1990–4 and
the follow-up study, ECRHS II, in 1999–2001. The design of
ECRHS I and II has been published in detail [16,17].
The present study included 468 subjects from the random
sample of three of ECRHS II centers, Gothenburg (n=225) and
Uppsala (n=175) (both Sweden) and Turin (n=68) (Italy), who
have undergone stage 2 of ECRHS I and in ECRHS II have
answered the main questionnaire, performed measurements of
FENO, lung function tests and methacholine challenge. No subjects
on daily inhaled steroids and/or oral antileukotrienes were
included in the present analyses. Details regarding the selection
of the subjects in these three centers are available in another
publication [18].
Methacholine challenge
Methacholine challenge was carried out using a dosimeter
(Mefar, Brescia, Italy). Methacholine challenge dose-response
slope (‘‘slope’’) was calculated as the regression coefficient of
percentage decline in FEV1 on log dose of methacholine and then
reciprocally transformed to satisfy statistical assumptions of
multiple regression [19]. Its values range from 1 to 20. Two units
of change in ‘‘slope’’ corresponds to one unit of change in
log10(PD20), or 3.32 doubling doses [20]. This relationship has
been used to express the results in doubling doses in the
manuscript. After transformation a low "slope’’, like low PD20,
was indicative of increased bronchial responsiveness. All subjects
were instructed to refrain from smoking for at least 1 hour before
lung function and methacholine reactivity measurements.
Exhaled NO
Exhaled NO measurements were done according to ATS/ERS
recommendations [21]. Exhaled NO measurements were carried
out on a different day than methacholine challenge. Different
techniques and flow rates of measuring FENO were used in
different centers - offline measurements at 350 mL s
21 in Turin
and online measurements at 50 mL s
21 in Uppsala and Gothen-
burg. The methods are described in more detail in another
publication [18]. All subjects were instructed to refrain from
smoking for at least two hours before measurements of exhaled
NO, in order to exclude any potential confounding effects of acute
smoking.
Smoking habits, atopy and asthma diagnosis
Smoking habits were questionnaire-assessed. A subject was
considered as being a current smoker if he/she had been smoking
for more than one year or at least 20 packs of cigarettes and was
still smoking the month before the study. The number of smoked
cigarettes per day and cigarette consumption in pack-years was
also questionnaire-assessed.
Specific IgE was measured against Dermatophagoides pteronyssi-
nus, cat, timothy grass and Cladosporium herbarum, using the
Pharmacia CAP System (Pharmacia Diagnostics, Uppsala,
Sweden). A person was defined as atopic if the titers against at
least one of the tested allergens were $0.35 kU/L.
Current asthma diagnosis was defined having self-reported
physician-diagnosis of asthma and at least one asthma symptom or
taking regular antiasthmatic medication during the last 12 months
preceding the study.
Lung function
Forced expiratory volume in one second (FEV1) was measured
with a standardized method with different spirometers in different
study centers, as previously described [18]. FEV1 was expressed as
% of the predicted value [22].
Statistics
Statistical analyses were performed using STATA 8.0 software
(Stata Corp., 2001, Texas, USA). Different FENO measurement
techniques [23], NO analysers [24] and exhalation flow rates were
used and we therefore divided FENO in quartiles for each centre
and pooled the data for the three centers instead of analyzing the
absolute values of FENO for each centre.
Trend tests were applied when analyzing the association
between FENO quartiles and other variables (Table 1). Simple
linear regressions between slope values and FENO quartiles were
performed. Interactions with smoking and atopy were studied in
multiple linear regression models where adjustments were made
for factors known, from literature, to affect bronchial responsive-
ness and FENO. The interactions were also tested by a meta-
analysis of corresponding multiple regression linear models when
using absolute value of FENO instead of FENO quartiles for the
respective three study centers. Heterogeneity between centers
regarding the interaction of smoking respectively atopy with the
relation between FENO and bronchial responsiveness was tested by
means of a meta-analysis of the three centers. A p-value of ,0.05
was considered statistically significant.
Results
The characteristics of the study population are presented in
Table 1. Subjects with higher FENO levels were characterized by a
higher prevalence of atopy and lower prevalence of current
smoking, whereas no significant association was found between
FENO and slope values. Male gender, current asthma as well as
increased height and weight, were associated with increased FENO
levels.
Selection bias – participants vs. non-participants
Participants who performed FENO measurements were more
likely to be men (50 vs. 44%, p=0.02) and had a slightly higher
mean age (43.260.3 vs. 41.260.3 years, p,0.0001) than
participants who did not undergo FENO measurements. No
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siveness, smoking habits, atopy, physician diagnosed asthma,
current asthma or body mass index between subjects who
performed FENO measurements and subjects who did not.
Effects of atopy and smoking on FENO
Dividing the subjects after current smoking and atopy status
(information available in 438 subjects), we obtained four groups:
non-smoking non-atopic (n=251), non-smoking atopic (n=107),
smoking non-atopic (n=57) and smoking atopic subjects (n=23).
Comparing the distribution of subjects into different FENO
quartiles in the above mentioned groups, the group of non-
smoking non-atopic subjects had lower FENO levels than the group
of non-smoking atopic subjects (p=0.01) and higher values than
the smoking non-atopic subjects (p,0.001) (Figure 1). No
differences in FENO were found between non-smoking non-atopics
and the smoking atopic subjects (p=0.96).
Effects of smoking status on the relationship between
bronchial responsiveness and FENO
Among non-smokers increased bronchial responsiveness was
associated with increased FENO values while an opposite trend was
seen among current smokers (Figure 2). There was a statistically
significant difference in the association between slope and FENO in
non- and current smokers (p-value for interaction=0.004).
In Table 2 the results are expressed as doubling doses of
methacholine. The interaction between smoking and FENO in
relation to bronchial responsiveness remained significant after
adjusting for gender, study centre, FEV1(%pred), age, height,
weight, atopy, current asthma (Table 2). When stratifying for
atopy, a significant interaction of smoking status with FENO
quartiles on airway responsiveness was found only among atopic
subjects (Table 2). No heterogeneity was found between centers
regarding the interaction of current smoking with the association
bronchial responsiveness and FENO (p=0.60). Significant trends
for increasing bronchial responsiveness with increasing FENO
levels were found in all subjects (p=0.009) and atopic subjects
(p=0.004) when a subanalysis was performed in Uppsala and
Gothenburg centers. Moreover, the interactions with smoking
remained statistically significant for all subjects (p=0.012) and
atopic subjects (p=0.018).
The interaction between smoking and FENO in relation to
bronchial responsiveness was also found when FENO was
expressed as absolute FENO values (p=0.01).
The number of smoked cigarettes was correlated negatively to
slope (p=0.003) and current smokers who showed the lowest
quartile of FENO were those who were smoking more cigarettes
and had a higher pack-years consumption (p=0.002 and
p=0.003, see Table 1). Nevertheless, the cigarette consumption
in pack-years was not significantly related to slope (p=0.18).
Table 1. Descriptive table of subjects divided according to their FENO levels (n (%) or arithmetic mean 6 SD or arithmetic mean
(95%CI)).
FENO Q1 (n=115) FENO Q2 (n=118) FENO Q3 (n=117) FENO Q4 (n=118) p-value
Slope
{ 7.8662.16 7.7861.80 7.9161.63 7.5162.06 0.25
Atopy
{ 20 (18.5%) 30 (26.5%) 36 (31.9%) 45 (40.9%) ,0.001
Current smoking
1 37 (32.5%) 21 (18.1%) 15 (12.9%) 11 (9.5%) ,0.001
Cigarettes/day 14 (11, 17) 11 (6, 15) 8 (4, 12) 6 (2, 11) 0.002
Pack-years 22 (18, 26) 16 (10, 23) 16 (11, 20) 11 (3, 19) 0.003
Male gender 45 (39.1%) 58 (49.1%) 72 (61.5%) 76 (64.4%) ,0.001
Height (cm) 169.368.4 172.869.1 174.8610.5 175.3611.0 ,0.001
Weight (kg) 74.0615.2 76.9614.8 77.5614.2 78.2615.2 0.03
BMI (kg/m
2) 25.764.23 25.663.73 25.363.53 25.363.65 0.36
Age (years) 43.267.59 43.267.43 43.867.10 42.266.81 0.46
Current asthma
# 5 (4.4%) 4 (3.5%) 4 (3.4%) 13 (11.2%) 0.03
FEV1 (%pred) 105613 107614 110613 107613 0.22
All the given p-values are for trends across FENO quartiles.
{Methacholine challenge dose-response slope.
{Information on atopy status was missing in 24 patients.
1Information regarding smoking habits was missing in 6 patients.
#Information regarding current asthma was lacking in 6 patients.
doi:10.1371/journal.pone.0035725.t001
Figure 1. Number of subjects in each FENO quartile (FENO Q1–
Q4) for non-smoking non-atopics, non-smoking atopics, smok-
ing non-atopics and smoking atopics, respectively.
doi:10.1371/journal.pone.0035725.g001
Smoking Effects on Relation between FENO and BHR
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35725Dividing current smokers into two groups, a positive association
between slope and FENO quartile could be seen only in the group
smoking less ,10 cigarettes/day (p=0.008) and not in the group
smoking $10 cigarettes/day (p=0.81) (Figure 3). These relations
were consistent after adjusting for pack-years consumption, and
also after additional adjustments for age, gender, height, weight,
lung function, current asthma, atopy, study centre (p=0.03).
Performing in such a model a test of interaction of ‘‘light’’/
‘‘heavy’’ smoking with FENO quartile on bronchial responsiveness
a trend towards a significant interaction was found (p=0.055).
The positive association between slope and absolute levels of FENO
could be found in subjects smoking less than 10 cigarettes/day in
Gothenburg and less than 13 cigarettes/day in Uppsala (both
p,0.05) (Table S1).
Effect of atopy on the relationship between bronchial
responsiveness and FENO
A positive correlation was found between increased bronchial
responsiveness (decrease of slope) and increased FENO among the
atopic subjects whereas no significant correlation was found
among the non-atopics (Figure 4, Table 3). The difference in
association between bronchial responsiveness and FENO in atopics
and non-atopics was statistically significant and the interaction of
atopy with FENO quartiles on bronchial responsiveness remained
statistically significant after adjusting for gender, study centre,
FEV1(%pred), age, height, weight, atopy, current asthma (Table 3).
No significant heterogeneity between centers was found regarding
the interaction of atopy with the association between slope and
FENO (p=0.13).
Dividing the participants into non-smokers and smokers the
relationship between bronchial hyperresponsiveness and FENO
was found to be significant only among non-smoking subjects
(Table 3).
Significant trends for increasing bronchial responsiveness with
increasing FENO levels were found in all atopic subjects (p=0.033)
and all atopic, non-smoking subjects (p=0.004) when a sub-
analysis was performed in Uppsala and Gothenburg centers.
Moreover, the interactions with atopy remained statistically
significant for atopic subjects (p=0.04).
The interaction of atopy with the relationship between slope
and FENO was also found to be significant when using absolute
FENO values (p=0.01).
Three-way interaction between atopy, smoking and FENO
on bronchial responsiveness
In a model where bronchial responsiveness was the outcome
and three-way interactions between atopy, smoking and FENO
were tested, only the interaction between atopy with FENO on
bronchial responsiveness was significant (p=0.005). This was
consistent after adjusting for gender, study centre, FEV1(%pred),
age, height, weight, atopy, current asthma (p=0.003). The three-
way interaction of smoking with atopy with FENO on bronchial
Figure 2. Methacholine challenge dose-response slope for all
subjects divided upon their FENO quartiles values and smoking
status. Data is presented as mean values 6 standard error of the mean
and a regression line (p-value in the brackets) is drawn for non- and
current smokers, respectively.
doi:10.1371/journal.pone.0035725.g002
Table 2. The difference (D) in bronchial responsiveness (BR), expressed as doubling doses of methacholine
1, between the first
FENO quartile (Q1) and the other quartiles (Q2–Q4) in all subjects, atopics and non-atopics, after stratifying for smoking.
Difference in BR Non-smokers Current smokers pinteraction
All subjects (n=432) DQ1–Q2 0.83 0.08 0.011
#
DQ1–Q3 1.00 20.91
DQ1–Q4 1.29 21.23
ptrend
* 0.015 0.17
Atopics (n=128) DQ1–Q2 1.58 20.28 0.008
DQ1–Q3 2.46 21.39
DQ1–Q4 3.68 23.87
ptrend
* ,0.001 0.11
Non-atopics (n=304) DQ1–Q2 0.68 0.02 0.22
DQ1–Q3 0.63 21.23
DQ1–Q4 0.35 20.88
ptrend
* 0.60 0.31
1Slope was the outcome of the regression model and doubling doses were obtained by multiplying the regression coefficients with 1.66, as described in the Methods.
*p-value for trend represents the statistical significance for the association between bronchial responsiveness and FENO quartile (used as a qualitative variable).
#p-value for interaction represents the significance of interaction of smoking status with FENO quartile on airways responsiveness.
All the coefficients and p-values are adjusted for gender, study centre, FEV1(%pred), age, height, weight, atopy, current asthma.
doi:10.1371/journal.pone.0035725.t002
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adjusted model (p=0.12).
Discussion
The main finding of the present study is that bronchial
responsiveness is associated with increased FENO levels in non-
smokers and with decreased FENO levels in current smokers.
Actually the inverse relationship between FENO and bronchial
responsiveness was significant only in ‘‘light’’ smokers, suggesting
possible different mechanisms of bronchial responsiveness in
‘‘light’’ and ‘‘heavy’’ smokers. Increased bronchial responsiveness
was associated with increased FENO in atopic subjects while no
such relationship could be seen in non-atopics. The nature of the
interactions on the relationship between FENO and bronchial
responsiveness with smoking and atopy appears to be even more
complex, since the interaction with smoking was seen only in
atopics, while the interaction with atopy was seen only in non-
smokers.
We think there are many reasons why the inverse relationship
between FENO and bronchial responsiveness in smokers cannot be
explained simply by considering the negative effect of smoking on
FENO, on one hand, and the favoring effect of smoking on
bronchial hyperesponsiveness [25], on the other hand, without a
causal relationship between the two effects. First, constitutively
produced NO may play a bronchoprotective role, which should be
lost in smokers, due to a lower NOS-production of NO [26,27] or
an increased catabolism of NO [28,29]. Evidence for a
bronchoprotective role of NO exist both in experimental animal
studies [30] [31], but also in human studies performed in
asthmatic subjects [32] [33] where administration of different
non-selective iNOS inhibitors resulted in increased bronchial
responsiveness. Another possible explanation could be related to
the smoking-induced neutrophil inflammation. Sputum neutro-
phils count has been found to be negatively correlated to FENO in
smokers [34] and activation of neutrophils, in vitro, has been shown
[35] to decrease NO, due to generation of peroxynitrite. Increased
IL-16 has been linked with the neutrophilic inflammation [36],
and IL-16 has been demonstrated to be increased in the airways of
cigarette smokers, independent on the intensity of smoking [37].
Epithelial and subepithelial IL-16 immunoreactivity has been
associated with increased bronchial responsiveness in humans with
allergic asthma [38] and in an animal model of allergic asthma
[39].
Moreover, in our study, decreased FENO was associated with
increased bronchial responsiveness only in ‘‘light’’ smokers, in
whom the bronchoprotective effect of NO may be particularly
valuable. Structural changes of small airways are related to
smoking amount [40] and thus, in ‘‘heavy’’ smokers, bronchial
hyperresponsiveness is best explained by structural changes of
small airways and lung parenchyma [41]. However, we acknowl-
edge the limitation that the different effects of ‘‘light’’ and ‘‘heavy’’
smoking on the association between FENO and bronchial
responsiveness could not be fully confirmed when performing a
statistical interaction test (p=0.055).
We were able to confirm in this large population sample that the
previous reported association between FENO and increased
bronchial responsiveness in adults [11–13] was significant only
in atopic subjects. Atopy-related increase in FENO is due probably
to the eosinophilic subclinical inflammation in the airways [42], as
the link between FENO and eosinophilic inflammation is well
known [43–45]. The mechanism behind increased bronchial
responsiveness in atopic subjects is most probably due to a
combination of subclinical eosinophilic inflammation and remod-
eling changes described in the airways of atopic subjects [46]. A
Th2-driven allergic response via IL-4-IL-13 cytokines could well
result in both increased NO [47,48] and increased bronchial
responsiveness [48,49].
The present study fills a gap regarding the effect of smoking on
the association between bronchial responsiveness and FENO and it
Figure 3. Effect size* (95%CI) for the association between slope and FENO (log-transformed) in non-, light (,10 cigarettes/day) and
heavy smokers ($10 cigarettes/day). * The effect size is the regression coefficient obtained by linear regression models with slope as outcome
and log-transformed FENO as dependent variable where the estimates of the three centres were combined by meta-analysis.
doi:10.1371/journal.pone.0035725.g003
Figure 4. Methacholine challenge dose-response slope for all
subjects divided upon their FENO quartiles values and atopy
status. Data is presented as mean values 6 standard error of the mean
and a regression line (p-value in the brackets) is drawn for non-atopics
and atopics, respectively.
doi:10.1371/journal.pone.0035725.g004
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smoking on the association between bronchial responsiveness and
FENO. The only group where we did find an association of
increased FENO values with increased bronchial responsiveness
was the group of non-smoking atopic individuals. We found
similar levels of FENO among the non-atopic non-smoking subjects
and atopic smoking subjects due to the fact that FENO is affected
both by smoking and atopy.
The main weakness of the present study resides in the different
methods to measure FENO in the participating centers. We used
quartiles of FENO instead of absolute values of FENO and no
heterogeneity between centers was found regarding the interaction
of smoking and atopy, respectively, with the relationship between
FENO and bronchial responsiveness. An indirect validation of this
method of using FENO quartiles in the present material is obtained
by confirming the previous results on the relationship between
FENO and bronchial responsiveness [11–13]. The fact that in one
center (Turin) FENO was measured by higher flow-rate, which
theoretically can sample to a slightly higher extent the peripheral
airways, appears to be scarcely influent in this study, as atopy does
not affect alveolar NO [50] and current smoking leads only to
minor decrease of alveolar in comparison with bronchial
contribution to exhaled NO [51]. Moreover, the main results
could be confirmed in a subanalysis performed only in Gothen-
burg and Uppsala. In our population sample atopic subjects are
underrepresented in the current smokers group, probably because
the subjects with atopy and bronchial hyperresponsiveness might
be less prone to start smoking. However this does not appear to
confound our results, since the proportion of atopics increase with
each FENO quartile among the smokers without any correspond-
ing increase in BR levels. COPD pathology is unlikely to have
affected the results of the present study, as no subjects have a
known COPD-diagnosis and only three subjects among the
current smokers had a FEV1/FVC-ratio ,0.70.
The difference in the relationships between bronchial respon-
siveness and exhaled NO in smokers and atopics respectively
suggests that atopy- and smoking cause bronchial hyperrespon-
siveness through different pathophysiological mechanisms. The
nature of the interactions between bronchial responsiveness and
exhaled NO is complex as the interaction with smoking could be
seen only in atopics while the interaction with atopy could be seen
only in non-smokers. Further studies are needed in order to
understand the mechanisms explaining how smoking and atopy
influence the relationship between bronchial responsiveness and
exhaled NO.
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